---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-23-000037"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2023-03-17T23:59:59+00:00"
generated_at: "2026-06-17T23:51:58.886078+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Xeris Biopharma replaces KPMG with Ernst & Young as independent auditor

## Summary
- Audit committee dismissed KPMG as independent registered public accounting firm on March 13, 2023.
- KPMG's reports for FY2022 and FY2021 had no adverse opinion except for a lease accounting change.
- No disagreements or reportable events occurred during the audit periods or interim period through March 13, 2023.
- Ernst & Young engaged as new independent auditor for the fiscal year ending December 31, 2023.

## SEC filing metadata
- accession: 0001867096-23-000037
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2023-03-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 4.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000037/0001867096-23-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000037/xers-20230313.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-23-000037
- JSON: https://secwatch.observer/filing/0001867096-23-000037.json
- Plain text: https://secwatch.observer/filing/0001867096-23-000037.txt

## Key facts
- Auditor Changes
  Xeris Biopharma Holdings, Inc. engaged Ernst & Young LLP as its auditor.
  - Action: engagement
  - Auditor: Ernst & Young LLP
  source text: On March 13, 2023, the Audit Committee of the Board approved the engagement of Ernst & Young LLP ("E&Y") as its new independent registered public accounting firm to audit the Company's financial statements for the fiscal year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000037/0001867096-23-000037-index.htm
- Auditor Changes
  Xeris Biopharma Holdings, Inc. dismissed KPMG LLP as its auditor.
  - Action: dismissal
  - Auditor: KPMG LLP
  - Successor: Ernst & Young LLP
  source text: On March 13, 2023, the audit committee (the "Audit Committee") of the board of directors (the "Board") of Xeris Biopharma Holdings, Inc. and subsidiaries (the "Company") approved the dismissal of KPMG LLP ("KPMG") as the Company's independent registered public accounting firm and KPMG was dismissed.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000037/0001867096-23-000037-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.